M
Mathijs A. Sanders
Researcher at Erasmus University Rotterdam
Publications - 119
Citations - 6856
Mathijs A. Sanders is an academic researcher from Erasmus University Rotterdam. The author has contributed to research in topics: Biology & Leukemia. The author has an hindex of 31, co-authored 90 publications receiving 4651 citations. Previous affiliations of Mathijs A. Sanders include Wellcome Trust Sanger Institute & Erasmus University Medical Center.
Papers
More filters
Journal ArticleDOI
Mutations in nucleophosmin (NPM1) in acute myeloid leukemia (AML): Association with other gene abnormalities and previously established gene expression signatures and their favorable prognostic significance
Roel G. W. Verhaak,Chantal S. Goudswaard,Wim H. van der Putten,Maarten A. Bijl,Mathijs A. Sanders,Wendy Hugens,André G. Uitterlinden,Claudia Erpelinck,Ruud Delwel,Bob Löwenberg,Peter J. M. Valk +10 more
TL;DR: It is demonstrated that patients with intermediate cytogenetic risk AML without FLT3 ITD mutations but with NPM1 mutations have a significantly better overall survival (OS) and event-free survival (EFS) than those without N PM1 mutations.
Journal ArticleDOI
A Single Oncogenic Enhancer Rearrangement Causes Concomitant EVI1 and GATA2 Deregulation in Leukemia
Stefan Gröschel,Stefan Gröschel,Mathijs A. Sanders,Remco Hoogenboezem,Elzo de Wit,Britta A M Bouwman,Claudia Erpelinck,Vincent H.J. van der Velden,Marije Havermans,Roberto Avellino,Kirsten van Lom,Elwin J. C. Rombouts,Mark van Duin,Konstanze Döhner,H. Berna Beverloo,James E. Bradner,Hartmut Döhner,Bob Löwenberg,Peter J. M. Valk,Eric M.J. Bindels,Wouter de Laat,Ruud Delwel +21 more
TL;DR: The data show that structural rearrangements involving the chromosomal repositioning of a single enhancer can cause deregulation of two unrelated distal genes, with cancer as the outcome.
Journal ArticleDOI
Molecular Minimal Residual Disease in Acute Myeloid Leukemia
Mojca Jongen-Lavrencic,Tim Grob,Diana Hanekamp,François G. Kavelaars,Adil Al Hinai,Annelieke Zeilemaker,Claudia A.J. Erpelinck-Verschueren,Patrycja L Gradowska,Rosa Meijer,Jacqueline Cloos,Bart J. Biemond,Carlos Graux,Marinus van Marwijk Kooy,Markus G. Manz,Thomas Pabst,Jakob Passweg,Violaine Havelange,Gert J. Ossenkoppele,Mathijs A. Sanders,Gerrit Jan Schuurhuis,Bob Löwenberg,Peter J. M. Valk +21 more
TL;DR: The detection of molecular minimal residual disease during complete remission had significant independent prognostic value with respect to relapse and survival rates, but the detection of persistent mutations that are associated with clonal hematopoiesis did not have such prognosticvalue within a 4‐year time frame.
Journal ArticleDOI
The landscape of somatic mutation in normal colorectal epithelial cells
Henry Lee-Six,Sigurgeir Olafsson,Peter D. Ellis,Robert J. Osborne,Mathijs A. Sanders,Mathijs A. Sanders,Luiza Moore,Nikitas Georgakopoulos,Franco Torrente,Ayesha Noorani,Ayesha Noorani,Martin Goddard,Philip Robinson,Tim H. H. Coorens,Laura O’Neill,Christopher Alder,Jingwei Wang,Rebecca C. Fitzgerald,Rebecca C. Fitzgerald,Matthias Zilbauer,Nicholas Coleman,Nicholas Coleman,Kourosh Saeb-Parsy,Inigo Martincorena,Peter J. Campbell,Michael R. Stratton +25 more
TL;DR: Genome sequencing of hundreds of normal colonic crypts from 42 individuals sheds light on mutational processes and driver mutations in normal colorectal epithelial cells, indicating that adenomas and carcinomas are rare outcomes of a pervasive process of neoplastic change across morphologically normal colorean epithelium.
Journal ArticleDOI
Prognostic impact, concurrent genetic mutations, and gene expression features of AML with CEBPA mutations in a cohort of 1182 cytogenetically normal AML patients: further evidence for CEBPA double mutant AML as a distinctive disease entity
Erdogan Taskesen,Lars Bullinger,Andrea Corbacioglu,Mathijs A. Sanders,Claudia Erpelinck,Bas J. Wouters,Sonja C P A M van der Poel-van de Luytgaarde,Frederik Damm,Jürgen Krauter,Arnold Ganser,Richard F. Schlenk,Bob Löwenberg,Ruud Delwel,Hartmut Döhner,Peter J. M. Valk,Konstanze Döhner +15 more
TL;DR: It is proposed that CEBPA(dm) should be clearly defined from CEbPA(sm) AML and considered as a separate entity in the classification of AML.